These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 12515970)
1. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis]. Celi M; Letizia C; Ragno A; Minisola S; D'Erasmo E; Mazzuoli GF Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970 [TBL] [Abstract][Full Text] [Related]
2. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover]. Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826 [TBL] [Abstract][Full Text] [Related]
3. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women. D'Amelio P; Muratore M; Tinelli F; Tamone C; Cosentino L; Quarta E; Calcagnile F; Carlo Isaia G Int J Tissue React; 2003; 25(2):73-8. PubMed ID: 14518596 [TBL] [Abstract][Full Text] [Related]
4. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis]. Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505 [TBL] [Abstract][Full Text] [Related]
5. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962 [TBL] [Abstract][Full Text] [Related]
6. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis. Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479 [TBL] [Abstract][Full Text] [Related]
7. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial. Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377 [TBL] [Abstract][Full Text] [Related]
8. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis. Sanad Z; Ellakwa H; Desouky B Climacteric; 2011 Jun; 14(3):369-77. PubMed ID: 21254911 [TBL] [Abstract][Full Text] [Related]
9. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW Menopause; 2003; 10(4):337-44. PubMed ID: 12851517 [TBL] [Abstract][Full Text] [Related]
10. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885 [TBL] [Abstract][Full Text] [Related]
11. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis. Iwamoto J; Takeda T; Sato Y; Uzawa M J Bone Miner Metab; 2005; 23(3):238-42. PubMed ID: 15838627 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience. Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis. Dane C; Dane B; Cetin A; Erginbas M Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771 [TBL] [Abstract][Full Text] [Related]
14. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775 [TBL] [Abstract][Full Text] [Related]
15. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083 [TBL] [Abstract][Full Text] [Related]
16. [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women]. Zheng SR; Wu YY; Zhang ZL; Yang X; Hui Y; Zhang Y; Chen SL; Den WH; Liu H; Ekangaki A; Stocks J; Harper K; Liu JL Zhonghua Fu Chan Ke Za Zhi; 2003 Apr; 38(4):226-9. PubMed ID: 12885371 [TBL] [Abstract][Full Text] [Related]
17. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449 [TBL] [Abstract][Full Text] [Related]
18. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192 [TBL] [Abstract][Full Text] [Related]
19. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women. Bolanca S; Korsić M; Dekanić D; Cvijetić S Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438 [TBL] [Abstract][Full Text] [Related]
20. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]